Response to the paper titled “Identification of a novel *CACNA1A* mutation in a Chinese family with autosomal recessive progressive myoclonic epilepsy”

Tracey D Graves

Department of Neurology, North West Anglia NHS Foundation Trust, Hinchbrook Hospital, Huntingdon, UK

Dear editor

I have just read this article.¹ I have issues with the authors denoting the insertion of CAG as a new mutation. This is located within a polyglutamine tract, which is known to be polymorphic in this gene. The normal number of CAG repeats in exon 47 of the *CACNA1A* gene ranges from 4 to 18; over 21 CAG repeats lead to the neurological condition SCA6.² Indeed, in this paper, Lv et al¹ call the mutation insertion c.6975_6976insCAG, that is, the insertion of one CAG codon; however, on the sequencing figure, the two affected members of the pedigree have 14 CAG repeats, whereas the control and unaffected descendant have 11 repeats. So, if they were going to call this a mutation, it would be an insertion of three CAG repeats. They also seem somewhat confused about the nature of this mutation, as in a later figure they suggest that the insertion of glutamine also causes deletion of alanine, which is not backed up by the data given on their sequencing figure, showing an in-frame insertion of CAG, which would not delete the following alanine residue.¹

This is a known polymorphism and, therefore, cannot be attributed to be the cause of disease in these patients.

Disclosure

The author reports no conflicts of interest in this communication.

References

1. Lv Y, Wang Z, Liu C, Cui L. Identification of a novel *CACNA1A* mutation in a Chinese family with autosomal recessive progressive myoclonic epilepsy. *Neuropsychiatr Dis Treat*. 2017;19(13):2631–2636.
2. Zhuchenko O, Bailey J, Bonnen P, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. *Nat Genet*. 1997;15(1):62–69.

Correspondence: Tracey D Graves
North West Anglia NHS Foundation Trust, Hinchbrook Hospital,
Hinchbrook Park, Huntingdon
PE29 6NT, UK
Email tracey.graves@nhs.net

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Neuropsychiatric Disease and Treatment ‘letters to the editor’ section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Neuropsychiatric Disease and Treatment editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Neuropsychiatric Disease and Treatment

Dovepress

Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the ‘PsycINFO’ database and CAS,

and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal>